Almost all patients with myeloma relapse, and there are multiple new options to treat patients with relapsed myeloma. Multiple factors need to be considered in determining the specific treatment for each patient at the time of relapse. This includes factors such as risk stratification, speed and aggressiveness of the relapse, nature and response to prior therapy, and eligibility for stem cell transplant. Dr. Rajkumar will review the various new treatments for relapsed myeloma including monoclonal antibodies, newer proteasome inhibitors, and other active regimens. He will provide a clear practical algorithm for treatment of first and subsequent relapses.
S. Vincent Rajkumar
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members